TO THE EDITOR Identification of recurrent mutation in the BRAF oncogene in melanoma has led to the development of highly selective kinase inhibitors (Larkin et al., 2014) . Although dramatic treatment responses are initially observed, responses are rarely durable. The mutational classification based on BRAF, NRAS, and NF1 mutations that has been established, however, is nonoverlapping with classification derived from gene expression profiling (The Cancer Genome Atlas Network [TCGA], 2015; Jö nsson et al., 2010) . In 2010, we reported four expression-based melanoma subtypes (the Lund subtypes): the high-immune, normal-like, microphthalmia-associated transcription factor (MITF)-high pigmentation, and MITF-low proliferative groups (Jönsson et al., 2010) . The high-immune group was distinguished by elevated expression of immune genes, the normal-like group by genes expressed in surrounding normal cells; the MITFhigh pigmentation and the MITFlow proliferative groups displayed increased expression of cell-cycle genes, and the MITF-low proliferative group had decreased expression of melanocyte differentiation genes. These subtypes were derived in stage IV tumors (Jö nsson et al., 2010) , but have since been firmly established in primary tumors (Harbst et al., 2012; Nsengimana et al., 2015) and stage III tumors (Cirenajwis et al., 2015) . In 2015, a TCGA landmark study reported three melanoma gene expression subtypes (TCGA, 2015) . The immune group was characterized by increased expression of immune genes; the keratin group was characterized by overexpression of keratin, pigmentation and epithelial genes; and the MITF-low group displayed decreased expression of melanocyte differentiation genes and activation of genes involved in nervous system development. However, it is not clear how the biological processes underlying the classification schemes relate to each other. Here, we compare bioinformatically derived biological pathways between the TCGA and Lund subtypes to search for evidence that both classification schemes identify similar biological entities, which may prove to be relevant in patient care.
To compare the TCGA and Lund classification schemes, we first investigated the two reported gene sets. Of the 1,500 TCGA genes used for subtype discovery, only 34 overlapped with the 486 Lund genes (Figure 1a ). Despite this limited overlap, gene ontology-term analysis showed similar biological processes enriched (false discovery rate < 0.01) in the two gene sets, including immunological processes (e.g., immune response, TCGA; response to wounding, Lund), melanocyte development (e.g., epidermis development, TCGA; pigmentation, Lund), and cell adhesion (e.g., cellular adhesion, TCGA and Lund). In addition, neuronal development processes were enriched in the TCGA gene set alone (see Supplementary Figure S1 online). Next, we investigated whether absolute expression levels of the TCGA and Lund gene sets differed (see Supplementary Materials online). Most TCGA genes were expressed at remarkably low levels, whereas the Lund genes were drawn from the entire expression range Figure 1A ). This suggests that the limited gene overlap between the TCGA and Lund classification schemes was caused by the technical relationship of intensity and variance (see Supplementary Figure S1 ), not by biological divergence. Collectively, although the gene sets were obtained from different expression ranges, they represent similar biological processes.
Next, we compared actual sample classifications between the TCGA and Lund schemes. First, we classified the 329 TCGA samples (TCGA, 2016) (Table 1) according to the Lund subtypes (Cirenajwis et al., 2015) . An extensive overlap between TCGA and Lund classification schemes was observed (Figure 1b) . Specifically, the TCGA immune group consisted of the Lund high-immune group (88%) plus 55% of MITF-high pigmentation group samples. The TCGA keratin group consisted predominantly of the Lund normal-like and MITF-high pigmentation groups, whereas the TCGA MITFlow group contained 76% of the Lund MITF-low proliferative tumors. Next, we applied the TCGA subtypes to the published Bergen (Jö nsson et al., 2010) (GSE33153), Lund (Cirenajwis et al., 2015) (GSE65904) and Leeds (Nsengimana et al., 2015 ) (E-MTAB-4725) datasets, which have pre-existing Lund subtype classifications. The fraction of subtypes differed between datasets, according to specimen site. The primary cohort of Leeds and the primary samples of the other datasets displayed small fractions of the highimmune and immune subtypes and high fractions of normal-like and keratin samples, whereas regional metastases contained few normal-like and keratin samples (see Supplementary  Figure S2 interrelated in a similar way in all three datasets, as already observed in the TCGA dataset (Figure 1b) , validating the overlap of the two subtyping schemes. Because the TCGA subtypes consist of three groups and the Lund subtypes of four groups, we derived four consensus clusters from the TCGA data for straightforward comparison (see Supplementary Figure S3 online). A cluster appeared that included 95% of the samples of the normal-like group (Figure 1b) . Overall, these results show a high consensus between the TCGA and Lund classification schemes.
Next, we investigated how key melanoma genes and transcriptional programs were expressed across the subtypes to show the biological basis underlying the classification schemes. We recently described gene modules, capturing major expression directions in melanoma (Cirenajwis et al., 2015) . The MITF-module was up-regulated in the keratin, normallike, and MITF-high pigmentation groups and down-regulated in the MITF-low and MITF-low proliferative groups (Figure 1c ). In addition, markers of melanoma cell states and neural crest progenitors were differentially expressed across subtypes (Figure 1c) . Markers of cytotoxic T cells (CD8A), B cells (CD19), and regulatory T cells (FOXP3), as well as the immune response module, were up-regulated in the immune and high-immune groups. Targets of immune checkpoint blockade agents, CTLA4 and PD-1, were also highly expressed in the immune and high-immune groups (Figure 1d ). Overall, key melanoma genes displayed analogous expression in the immune and high-immune groups; keratin, normal-like, and MITF-high pigmentation groups, and MITF-low and MITFlow proliferative groups. We therefore argue that these sets of subtypes have distinct biological backgrounds.
The immune groups (immune and high-immune) had favorable survival rates compared with the remaining groups in patients with metastatic samples from TCGA, Bergen, and Lund and in the primary Leeds cohort (Figure 1e) , confirming previous reports. Most patients were recruited before systemic treatment; thus, the treatment-predictive significance of the subtypes could not be assessed. However, there is emerging evidence that expression of immune genes may predict response to immune checkpoint blockade (Van Allen et al., 2015) . Further studies are needed to determine the treatment predictive value of gene expression subtypes.
Collectively, melanoma gene expression patterns are determined along the trajectories of melanocyte differentiation and mitotic genes, and genes expressed in surrounding/infiltrating immune cells and stroma. Single genes may deviate from these patterns; however, we show that genome-wide expression analysis converges on fundamental melanoma entities, as represented by the TCGA and Lund subtypes.
